MHC Class II HLA-DP/DQ/DR anticorps
-
- Antigène Tous les produits MHC Class II HLA-DP/DQ/DR (HLA-DP/DQ/DR)
- MHC Class II HLA-DP/DQ/DR (HLA-DP/DQ/DR)
-
Reactivité
- Humain
-
Hôte
- Souris
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp MHC Class II HLA-DP/DQ/DR est non-conjugé
-
Application
- Flow Cytometry (FACS)
- Fonction
- Anti-HLA-DR,DP,DQ Unconjugated Antibody
- Attributs du produit
- The clone IVA12 recognizes the shared epitopes of human leucocyte antigen (HLA) class II molecules HLA-DP, HLA-DQ and HLA-DR heterodimeric cell surface glycoproteins comprised of an α (heavy) chain and a β (light) chain. They are expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional antigen presenting cells (APCs). HLA-Class II expressing APCs specifically present antigens recognized by TCR/CD3 complex of CD4+ T cells. Reactive microglia and perivascular cells in multiple sclerosis lesions express all three types of HLA-Class II molecules, whereas microglia in the normal CNS expressed HLA-DR only.
- Purification
- Purified
- Pureté
- >95 %
- Classe de qualité
- GMP Grade
- Immunogène
- Priess human B cell line
- Clone
- IVA12
- Isotype
- IgG1, kappa
-
-
- Indications d'application
- Each lot of this antibody has been pre-titrated and tested by flow cytometric analysis of human PBMCs such that 0.5µg is sufficient for staining 1 million cells in a 100µl staining volume or 100µl of whole blood. It is recommended to titrate antibody reactivity empirically for optimal performance.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- PBS pH 7.2, 0.1 % (w/v) BSA, 0.09 % (w/v) sodium azide
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- 4 °C
-
- Antigène
- MHC Class II HLA-DP/DQ/DR (HLA-DP/DQ/DR)
- Autre désignation
- HLA-DR, DP, DQ (HLA-DP/DQ/DR Produits)
- Pathways
- Human Leukocyte Antigen (HLA) in Adaptive Immune Response
-